PB2-IN-2

PB2-IN-2 is an orally active PB2 inhibitor with RNP inhibitory activity (IC50) of 0.2 nM, cellular level replication inhibition activity (LRAEC50) of 0.8 nM, and cytopathic effect inhibition activity (CPEEC50) of 0.1 nM. It demonstrates nanomolar range broad-spectrum antiviral efficacy against various influenza A strains, including H1N1pdm09, Lyon/1337/2007/H1N1, Tex12-Like/H3N2, PR/8/34/H1N1, WSN/1933/H1N1, and rPR8 (H1N1) /H7N9, with EC50 values of 1.5, 3.6, 3.7, 13.8, 2.9, and 9.8 nM, respectively, and CC50 values all greater than 2 μM. PB2-IN-2 also shows excellent metabolic stability and pharmacokinetic properties, making it suitable for influenza research.